NovaBridge Secures FDA Alignment on Accelerated Approval Pathway for Givastomig
Event summary
- NovaBridge received written minutes confirming FDA alignment on an accelerated approval pathway for givastomig in 1L Her2-, CLDN 18.2+, PD-L1+ GEC patients.
- The company plans to initiate a registrational Phase 3 combination trial in Q4 2026, using objective response rate (ORR) as the primary endpoint.
- Phase 1b data showed a 75% ORR with givastomig in combination with immunochemotherapy, alongside a median progression-free survival (mPFS) of 16.9 months.
- Givastomig is jointly developed with ABL Bio, with NovaBridge holding worldwide rights excluding Greater China and South Korea.
The big picture
NovaBridge's progress with givastomig underscores the increasing focus on targeted therapies for gastroesophageal cancer, a market with significant unmet need. The accelerated approval pathway, if realized, would significantly shorten the time to market and provide a competitive advantage, but also carries the risk of post-approval scrutiny if confirmatory trials fail to validate initial findings. The partnership with ABL Bio, while beneficial for resource sharing, introduces a layer of complexity in decision-making and potential conflict.
What we're watching
- Regulatory Risk
- While the Type B meeting was positive, final approval hinges on Phase 3 trial success and FDA acceptance of ORR as a primary endpoint, introducing potential regulatory hurdles.
- Clinical Execution
- The rapid timeline for Phase 3 initiation (Q4 2026) suggests aggressive execution; delays in patient enrollment or trial design could impact the accelerated approval pathway.
- Partner Dynamics
- The shared rights structure with ABL Bio introduces potential for disagreements regarding development strategy or commercialization, which could impact givastomig’s progress.
Related topics